Forensic Audit of Primary Literature on Alcoholic Liver Disease: Phytochemical Synergies, Signaling Cascades, and Cellular Fate Protocols

The clinical management of alcoholic liver disease (ALD) has historically relied on abstention and supportive care, but emerging forensic audits of primary pharmacological literature suggest that a sophisticated intersection of phytochemical synergies and targeted signaling modulation offers a superior therapeutic trajectory. ALD is characterized by a multi-stage progression, initiating as alcoholic fatty liver (AFL) or steatosis, potentially advancing to alcoholic hepatitis (AH), and culminating in cirrhosis or hepatocellular carcinoma.[1] The pathogenesis is driven by the metabolic toxicity of ethanol and its primary metabolite, acetaldehyde, alongside systemic inflammation, oxidative stress, and the disruption of the gut-liver axis.[3]

Phytochemical Synergies in Alcohol Metabolism and Detoxification

The initial hit in ALD pathogenesis is the saturation of the hepatic metabolic capacity. Ethanol is primarily oxidized by alcohol dehydrogenase (ADH) to acetaldehyde, which is further metabolized by aldehyde dehydrogenase (ALDH) to acetate.[6] When these pathways are overwhelmed, reactive oxygen species (ROS) production escalates, and toxic intermediates accumulate, necessitating the exploration of herb-pair synergies to accelerate metabolic flux.

The Pueraria-Hovenia Synergy and Biotransformation Dynamics

The combination of *Puerariae Radix* (PR) and *Hovenia Seed* (HS) serves as a paradigm for synergistic metabolic enhancement. PR is recognized for its ability to accelerate gastrointestinal motility and initial ethanol breakdown, whereas HS provides complementary diuretic and laxative properties that facilitate toxin clearance.[6] Forensic analysis of co-fermented extracts involving *Lactiplantibacillus plantarum* and *Lacticaseibacillus paracasei* reveals that biotransformation through fermentation significantly alters the flavonoid profile, enhancing therapeutic efficacy.[6]

Co-fermentation facilitates the cleavage of glycosidic bonds, which optimizes the structural bioavailability of core flavonoids. Quantitative assessments indicate that this process elevates total flavonoid, polysaccharide, and saponin content.[6] Specifically, the biotransformation process induces significant shifts in the isoflavone landscape, as detailed in the following analysis:

Flavonoid Component	Concentration Change (Post-Fermentation)	Functional Role in ALD
Puerarin	$+20\%$	Upregulates antioxidant enzymes; mitigates inflammation [6]
Daidzin	$+695\%$	Modulates metabolic rate; regulates alcohol-induced behavioral deficits [6]
Myricetin	$+84\%$	Provides hepatoprotective synergy; reduces transaminase levels [6]
Daidzein	-48%	Utilized as a biosynthetic precursor during fermentation [6]

The PR-HS combination demonstrates a potency superior to individual decoctions in delaying the alcohol-induced loss of righting reflex (LORR) and shortening sobriety recovery time.[6] This is achieved by the simultaneous activation of ADH and ALDH2, providing a dual-enzyme acceleration that reduces peak blood ethanol concentrations and mitigates the risk of acetaldehyde-mediated DNA damage.[6]

Multi-Component Formulations and Metabolic Optimization

Beyond the PR-HS pair, formulations involving *Silybum marianum* (Silymarin) and *Fructus Schisandrae* have been audited for their cumulative effects on the $ADH/ALDH$ system. The *Silymarin-Pueraria lobata-Prednisolone* triad is predicted to target 95 specific proteins involved in ALD, notably ALB, $IL6$, and TNF.[8] Molecular docking indicates high affinity for $ADH1C$, suggesting that this combination modulates lipid metabolism and inflammatory responses by alleviating ethanol-induced oxidative stress.[8]

Similarly, the *Semen Hoveniae-Radix Puerariae-Fructus Schisandrae* (SRF) composition inhibits ethanol absorption while promoting its metabolism. SRF-pretreated models exhibit lower area-under-the-curve (AUC) values for blood ethanol, corresponding to increased enzymatic activity in both the liver and the gastrointestinal tract.[7] These synergies provide a unique advantage by targeting ethanol at its entry point and its primary site of detoxification.

Gut-Liver Axis Homeostasis and Microbiota

Stabilization

The gut-liver axis represents a critical bidirectional pathway where gut-derived toxins, specifically lipopolysaccharides (LPS), translocate through a compromised intestinal barrier to trigger hepatic inflammation via the portal vein.[5] ALD-induced dysbiosis increases intestinal permeability, an effect termed "leaky gut," which is a primary driver of ALD progression.[11]

Cistanche tubulosa: Recalibrating the Microbiota-Immune Axis

Forensic audits of *Cistanche tubulosa* phenylethanoid glycosides (CPhGs) highlight their role in modulating the "gut-liver" axis to ameliorate alcoholic liver injury.[13] Chronic alcohol exposure causes the abnormal proliferation of *Allobaculum* and a decline in beneficial strains like *Akkermansia muciniphila*.[13] CPhGs intervention significantly increases *Akkermansia* abundance while decreasing *Allobaculum* levels, a shift that is intrinsically linked to propionic acid metabolism and intestinal mucus balance.[13]

CPhGs enhance the therapeutic outcome of ALD by:

1. **Restoring Mucus Integrity**: Upregulating the proliferation of goblet cells, which are responsible for secreting the protective mucus layer.[13]
2. **Modulating Short-Chain Fatty Acids (SCFAs)**: Increasing the concentration of intestinal SCFAs, which serve as essential energy sources for colonocytes and maintain tight junction proteins.[13]
3. **Inhibiting TLR4 Signaling**: Reducing serum LPS and hepatic lipopolysaccharide-binding protein (LBP) levels, thereby blocking the $LPS - TLR4/MyD88/NF - \kappa B$ pathway.[14]

The therapeutic efficacy of CPhGs is further validated by multi-omics analysis, which reveals the upregulation of $GOT1$ expression, suggesting a shift in amino acid metabolism that supports hepatic repair.[3]

Acanthus ilicifolius and Inflammatory Signal Attenuation

Acanthus ilicifolius extracts (EAI) exert hepatoprotective effects by directly targeting the $TLR4/NF - \kappa B$ signaling pathway and rebalancing the intestinal microenvironment.[15]

Audit data shows a dose-dependent reduction in AST, ALT, and ALP levels upon EAI administration.[15] The microbial shifts associated with EAI include the promotion of *Ligilactobacillus* and *Lactobacillus* species, which negatively correlate with serum transaminase levels, and the suppression of harmful *Helicobacter* and *Bacteroides*.[15]

By modulating the "microbiota-immune-metabolic axis," EAI prevents the translocation of endotoxins that would otherwise trigger the hepatic immune burden. This stabilization is

essential for halting the progression from isolated steatosis to fibrogenesis.[10]

Nrf2/HO-1 Nuclear Reprogramming and Redox Defense

The Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) axis is the master regulator of cellular antioxidant responses. Alcohol-induced oxidative stress typically leads to the $Keap1$-mediated ubiquitination and degradation of $Nrf2$, preventing its nuclear translocation.[16]

Piceatannol: The Dual Antioxidant and Anti-Ferroptosis Modulator

Piceatannol (PIC), a natural stilbene analog of resveratrol, has emerged as a superior modulator of the $Keap1 - Nrf2$ axis compared to its parent compound.[17] PIC disrupts the interaction between $Keap1$ and $Nrf2$, facilitating the nuclear translocation of $Nrf2$ and the subsequent activation of the downstream heme oxygenase-1 ($HO-1$) and glutathione peroxidase 4 ($GPX4$) pathways.[16]

Forensic evidence confirms that PIC's therapeutic efficacy is nullified by the $Nrf2$ inhibitor $ML385$, establishing its mechanism as pathway-dependent. PIC not only alleviates hepatic inflammation and oxidative stress but also specifically counteracts ferroptosis, an iron-dependent form of cell death characterized by lipid peroxide accumulation.[16] This dual action makes PIC a promising candidate for managing the severe oxidative burden of ALD.[16]

Baicalin and the non-canonical p62-Keap1-Nrf2 Cascade

Baicalin, isolated from *Scutellaria baicalensis*, activates $Nrf2$ through an alternative p62-dependent pathway.[19] In models of fatty liver disease, Baicalin upregulates the $p62 - Keap1 - Nrf2$ signaling cascade, where $p62$ competes with $Nrf2$ for binding to $Keap1$.[19] This sequestration of $Keap1$ allows $Nrf2$ to escape degradation and enter the nucleus to initiate the transcription of antioxidant response elements (ARE).[19] Baicalin's ability to polarize macrophages toward the anti-inflammatory $M2c$ subtype further emphasizes its role in metabolic and immune reprogramming.[21]

NLRP3 Inflammasome Inhibition and the Resolution of Inflammation

The NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome is a pivotal mediator of the inflammatory response in ALD. Its activation requires two signals: Signal I (priming via $NF-\kappa B$) and Signal II (activation via ROS, K^+ efflux, or lysosomal rupture).[2]

Quercetin and the HO-1/NLRP3 Interface

Quercetin, a potent dietary flavonoid, suppresses the $NLRP3$ inflammasome by targeting $HO-1$.[24] Forensic database analysis shows that $HO-1$ levels are significantly reduced in patients with acute alcoholic hepatitis.[25] Quercetin elevates $Nrf2/HO-1$ expression, which inhibits the $ROS/NF-\kappa B/NLRP3/IL-1\beta$ pathway.[24]

The role of $HO-1$ is critical; when Quercetin is combined with the $HO-1$ inhibitor $ZnPP-IX$, its hepatoprotective effects are diminished.[25] Quercetin also upregulates the anti-inflammatory factor $IL-10$, providing a multi-pronged approach to inflammatory resolution. The following table summarizes the modulatory effects of Quercetin on hepatic lipid and inflammatory markers:

Parameter	Response to Quercetin	Pathophysiological Impact
IL-1β, IL-18	Significant Reduction	Inhibition of pyroptosis and inflammatory storm [24]
TNF-α, IL-6	Significant Reduction	Mitigation of systemic and hepatic inflammation [4]
FAS, SCD1, ACC1	Downregulation	Suppression of de novo lipogenesis [4]
CPT1, PPARα	Upregulation	Enhancement of fatty acid β-oxidation [4]
SOD, GSH, CAT	Upregulation	Restoration of antioxidant capacity [4]

Scutellarin and Scutellarein: Signal II Suppression

Scutellarin (SCU), derived from *Erigeron breviscapus*, prevents acute alcoholic liver injury by inhibiting $CYP2E1$ upregulation and inducing the $Nrf2/HO-1$ pathway.[27] SCU specifically suppresses the degradation of $I\kappa B\alpha$, thereby inhibiting $NF-\kappa B$ (Signal I) and subsequently reducing the expression of AKT and $p38\ MAPK$.[27] Audit data also suggests that SCU inhibits $NLRP3$ activation in macrophages by augmenting PKA signaling, which blocks the assembly of the inflammasome complex (Signal II).[28] This provides a robust defense against the "cytokine storm" that drives AH toward cirrhosis.

Regulation of Lipid Flux and Bile Acid Homeostasis

Hepatic lipid accumulation is mediated by the dysregulation of the $AMPK-SREBP1-FASN$ (ASF) axis, where alcohol-induced dephosphorylation of $AMPK$ leads to uncontrolled fatty acid synthesis.[29]

Luteolin and Withaferin A: AMPK-Mediated Metabolic Control

Luteolin (LUT) and Withaferin A (WA) are potent activators of $AMPK$. LUT ameliorates metabolic dysfunction by upregulating the $AdipoR1/AMPK/PPAR\gamma$ signaling pathway.[30] Forensic studies indicate that LUT suppresses $SREBP-2$ expression and prevents its nuclear translocation, thereby reducing the transcription of $HMGCR$, the rate-limiting enzyme in cholesterol biosynthesis.[32] Furthermore, LUT enhances mitophagy through the $PINK1/Parkin$ pathway, which is essential for clearing damaged mitochondria in hepatocytes.[33]

WA, a steroidal constituent of *Withania somnifera*, alleviates ethanol-induced injury by inhibiting hepatic lipogenesis.[34] WA significantly reduces mRNA levels of $Srebp1c$, $Fasn$, $Acc1$, and $Fabp1$.[34] By decreasing lipid accumulation and hepatocyte death, WA acts as a metabolic stabilizer in the face of acute binge ethanol exposure.[34]

Kaempferol and the FXR-FGF15 Signaling Axis

Bile acid homeostasis is frequently disrupted in ALD, leading to cholestatic injury. Kaempferol (KAE) regulates this process by directly activating the intestinal farnesoid X receptor (FXR).[36] Activation of intestinal FXR induces $FGF15$ (the rodent ortholog of human $FGF19$), which travels to the liver to bind the $FGFR4/\beta-Klotho$ complex.[36] This signaling

cascade inhibits $CYP7A1$, the rate-limiting enzyme in bile acid synthesis, thereby reducing the hepatic bile acid pool and mitigating alcohol-induced injury.[36]

Programmed Cell Death Protocols: Ferroptosis and Autophagy

The terminal stages of hepatocyte injury in ALD involve programmed cell death protocols that either exacerbate or resolve the injury.

Ferroptosis: Iron Loading and Lipid Peroxidation

Ferroptosis is fueled by the accumulation of iron and the depletion of $GPX4$.[16] Ethanol metabolism promotes the conversion of Fe^{3+} to Fe^{2+}, triggering the Fenton reaction and massive ROS production.[1] Pueraria lobata root-derived exosome-like nanovesicles (P-ELNs) have been audited for their ability to suppress ferroptosis by inhibiting the elevation of acyl-CoA synthetase long-chain family member 4 ($ACSL4$) and preventing the reduction of $GPX4$ and GSH.[39] These nanovesicles demonstrate superior efficacy compared to pure puerarin, suggesting that the exosomal lipid and protein cargo provides additional therapeutic advantages.[39]

Autophagy: The Selective Quality Control Mechanism

Autophagy serves as a double-edged sword in ALD. While acute alcohol consumption triggers a protective autophagic response to clear damaged mitochondria (mitophagy) and lipid droplets, chronic exposure impairs these processes.[1] *Rabdosia rubescens* acts as a potent inducer of autophagy, increasing the expression of $LC3, Beclin-1,$ and $ATG7$ while decreasing $p62$.[42] By facilitating the phagocytosis of damaged mitochondria and excessive lipid droplets, *Rabdosia rubescens* promotes cell survival and maintains the stability of the hepatic internal environment.[42]

Forensic Tabulation of Substances, Precursors, and Logistics

A comprehensive forensic audit requires the detailed mapping of substance availability, chemical precursors, and potential substitutes to facilitate clinical and industrial application.

Substance	Precursors &	Natural	Substitutes	Commercial

	Biosynthetic Origins	Sources & Origins		Availability
Piceatannol	Hydroxylation of Resveratrol [17]	Grapes, *Picea abies*, Passion fruit [17]	Resveratrol, 3,5,4'-trimethoxystilbene [43]	High (Analytical & Supplement)
Baicalin	Uridine diphosphate glucuronidation of Baicalein [44]	*Scutellaria baicalensis*, *Oroxylum indicum* [20]	Baicalein, Oroxylin A, Wogonin [20]	High (Pharmaceutical Grade)
Withaferin A	Steroidal lactone oxidation [45]	*Withania somnifera* (Ashwagandha) [35]	Withanone, Withanolide D [45]	Moderate (Specialized Extract)
Scutellarein	Aglycone of Scutellarin [27]	*Erigeron breviscapus*, *Scutellaria* species [28]	Scutellarin, Apigenin, Luteolin [27]	Moderate (Extracts/HPLC Grade)
Luteolin	Biosynthesized via phenylalanine pathway [47]	Celery, Broccoli, Parsley, Honeysuckle [47]	Quercetin, Apigenin [32]	High (Widely Distributed)
Kaempferol	Derived from Naringenin [36]	Tea, Apples, Broccoli, Strawberries [36]	Quercetin, Myricetin [8]	High (Food & Supplement)
Puerarin	Isoflavone glucoside [39]	*Pueraria lobata* (Kudzu Root) [39]	Daidzin, Genistein [6]	High (Clinical TCM)
Silymarin	Complex of flavonolignans [50]	*Silybum marianum* (Milk Thistle) [50]	Silybin, Isosilybin [50]	High (Over-the-Counter)

The synthesis of these compounds often involves complex biochemical routes. For instance, Luteolin analogs can be produced via acetylation or propionylation methods, achieving yields of approximately $72 - 76\%$.[47] Conversely, Withaferin A is difficult to produce economically

through total synthesis due to its complex stereochemical structure, making the extraction from *Withania somnifera* the primary commercial route.[51]

Integrative Conclusions on the Forensic Audit of ALD Phytotherapy

The forensic audit of ALD primary literature reveals a high-resolution map of phytochemical interventions that transcend simple antioxidant supplementation. The synergistic pairing of *Pueraria* and *Hovenia* represents a optimized metabolic strike against ethanol and acetaldehyde, particularly when enhanced through biotransformation. The gut-liver axis interventions using *Cistanche tubulosa* and *Acanthus ilicifolius* address the systemic origin of inflammation by reinforcing the intestinal barrier and modulating propionic acid-producing commensals like *Akkermansia*.

Molecular signaling modulation via $Nrf2/HO-1$ reprogramming (Piceatannol, Baicalin) and $NLRP3$ inflammasome inhibition (Quercetin, Scutellarein) provides the nuclear and cytosolic control necessary to halt the progression of alcoholic hepatitis. Simultaneously, the regulation of lipid flux and bile acid homeostasis through the $AMPK/SREBP1$ and $FXR/FGF15$ axes prevents the development of chronic steatosis and cholestasis. Finally, the strategic management of cell-death protocols—specifically the inhibition of ferroptosis via P-ELNs and the induction of mitophagy via *Rabdosia rubescens*—ensures the preservation of hepatocyte structural integrity.

Future therapeutic strategies for ALD must leverage these multi-target synergies, moving away from single-agent interventions toward sophisticated phytochemical cocktails that recalibrate the metabolic, immune, and structural landscape of the liver. The integration of advanced delivery systems, such as plant-derived nanovesicles, further promises to enhance the bioavailability and precision of these naturally derived therapeutic agents.

Works cited

1. Molecular mechanisms of alcohol-associated liver disease-ferroptosis and autophagy crosstalk - ResearchGate, accessed May 6, 2026, https://www.researchgate.net/publication/390494167_Molecular_mechanisms_of_alcohol-associated_liver_disease-ferroptosis_and_autophagy_crosstalk
2. (PDF) NLRP3 Inflammasome Activation in Liver Disorders: From Molecular Pathways to Therapeutic Strategies - ResearchGate, accessed May 6, 2026, https://www.researchgate.net/publication/392946432_NLRP3_Inflammasome_Activation_in_Liver_Disorders_From_Molecular_Pathways_to_Therapeutic_Strategies
3. Potential of Cistanche tubulosa extract in attenuating acute alcoholic liver injury via modulation of oxidative stress and lipid metabolism - ResearchGate, accessed

May 6, 2026, https://www.researchgate.net/publication/397653565_Potential_of_Cistanche_tubulosa_extract_in_attenuating_acute_alcoholic_liver_injury_via_modulation_of_oxidative_stress_and_lipid_metabolism
4. Quercetin attenuates acute alcohol-induced liver injury in mice by modulating lipid metabolism, oxidative stress, and inflammation - Frontiers, accessed May 6, 2026, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1702639/full
5. The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC - MDPI, accessed May 6, 2026, https://www.mdpi.com/2227-9059/10/3/524
6. Enhanced Bioactivity of Puerariae Radix- Hovenia Seed Extracts ..., accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC13109719/
7. A Herbal Composition of Semen Hoveniae, Radix Puerariae, and Fructus Schisandrae Shows Potent Protective Effects on Acute Alcoholic Intoxication in Rodent Models - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3479684/
8. Predicting the mechanism of action of Silymarin —Pueraria lobata—Prednisolone combination in the treatment of alcoholic liver disease based on network pharmacology and molecular docking. - R Discovery, accessed May 6, 2026, https://discovery.researcher.life/article/predicting-the-mechanism-of-action-of-silymarin-pueraria-lobataprednisolone-combination-in-the-treatment-of-alcoholic-liver-disease-based-on-network-pharmacology-and-molecular-docking/025043bc9f84316f82227438326bb7ba
9. The gut-liver axis in fatty liver disease: role played by natural products - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11056694/
10. Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease, accessed May 6, 2026, https://www.gutnliver.org/journal/view.html?pn=mostcited&uid=2289&vmd=Full
11. Analyzing the gut liver axis: a dual role of the microbiome in the genesis, progression, and treatment of liver cell carcinoma - Frontiers, accessed May 6, 2026, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1701101/full
12. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6358912/
13. Protective effects of phenylethanol glycosides from Cistanche ..., accessed May 6, 2026, https://pubmed.ncbi.nlm.nih.gov/39395767/
14. Phenylethanol Glycoside from Cistanche tubulosa Attenuates BSA-Induced Liver Fibrosis in Rats by Modulating the Gut Microbiota–Liver Axis - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11435394/
15. Protective effect of Acanthus ilicifolius extracts against acute ..., accessed May 6, 2026, https://pubmed.ncbi.nlm.nih.gov/39222481/

16. Piceatannol alleviates oxidative stress and ferroptosis in alcohol ..., accessed May 6, 2026, https://pubmed.ncbi.nlm.nih.gov/40885093/
17. Predicting phase-I metabolism of piceatannol: an in silico study - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11153392/
18. Ferroptosis in Human Diseases: Fundamental Roles and Emerging Therapeutic Perspectives - MDPI, accessed May 6, 2026, https://www.mdpi.com/2076-3921/14/12/1411
19. Baicalin attenuated metabolic dysfunction-associated fatty liver disease by suppressing oxidative stress and inflammation via the p62–Keap1–Nrf2 signalling pathway in db/db mice - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12013857/
20. An overview of pharmacological activities of baicalin and its ..., accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9118284/
21. Potential therapeutic effects of baicalin and baicalein - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11210699/
22. Relevance of the NLRP3 Inflammasome in the Pathogenesis of Chronic Liver Disease, accessed May 6, 2026, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.01728/full
23. Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis - PMC - NIH, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10851067/
24. Targeting heme oxygenase-1 by quercetin ameliorates alcohol-induced acute liver injury via inhibiting NLRP3 inflammasome activation - ResearchGate, accessed May 6, 2026, https://www.researchgate.net/publication/326279994_Targeting_heme_oxygenase-1_by_quercetin_ameliorates_alcohol-induced_acute_liver_injury_via_inhibiting_NLRP3_inflammasome_activation
25. Targeting heme oxygenase-1 by quercetin ameliorates alcohol-induced acute liver injury via inhibiting NLRP3 inflammasome activation - PubMed, accessed May 6, 2026, https://pubmed.ncbi.nlm.nih.gov/29993075/
26. Quercetin attenuates acute alcohol-induced liver injury in mice by modulating lipid metabolism, oxidative stress, and inflammation - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12957255/
27. Scutellarin prevents acute alcohol-induced liver injury via inhibiting oxidative stress by regulating the Nrf2/HO-1 pathway and inhibiting inflammation by regulating the AKT, p38 MAPK/NF-κB pathways - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10350365/
28. Scutellarin Suppresses NLRP3 Inflammasome Activation in Macrophages and Protects Mice against Bacterial Sepsis - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5767189/
29. Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12918582/
30. Luteolin Relieves Metabolic Dysfunction-Associated Fatty Liver Disease Caused

by a High-Fat Diet in Rats Through Modulating the AdipoR1/AMPK/PPARγ Signaling Pathway - Semantic Scholar, accessed May 6, 2026, https://www.semanticscholar.org/paper/Luteolin-Relieves-Metabolic-Dysfunction-Associated-Taweesap-Potue/8599ad7bb902f9da8e64c89929723a31e9511323
31. Luteolin Relieves Metabolic Dysfunction-Associated Fatty Liver Disease Caused by a High-Fat Diet in Rats Through Modulating the AdipoR1/AMPK/PPARγ Signaling Pathway - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12028338/
32. The Flavone Luteolin Suppresses SREBP-2 Expression and Post-Translational Activation in Hepatic Cells | PLOS One - Research journals, accessed May 6, 2026, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135637
33. Luteolin attenuates LPS-induced damage in IPEC-J2 cells by enhancing mitophagy via AMPK signaling pathway activation - Frontiers, accessed May 6, 2026, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1552890/full
34. Withaferin A alleviates ethanol-induced liver injury by inhibiting ..., accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10353774/
35. Withaferin A: From Ancient Remedy to Potential Drug Candidate - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8705790/
36. Kaempferol ameliorated alcoholic liver disease through inhibiting ..., accessed May 6, 2026, https://pubmed.ncbi.nlm.nih.gov/37678053/
37. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4695634/
38. Modulation of the intestinal bile acid–FXR–FGF15 axis improves alcoholic liver disease in mice - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5962369/
39. Preparation of Pueraria lobata Root-Derived Exosome-Like ..., accessed May 6, 2026, https://pubmed.ncbi.nlm.nih.gov/38828197
40. The Emerging Role of Autophagy in Alcoholic Liver Disease - PMC - NIH, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4096159/
41. Autophagy, Oxidative Stress, and Alcoholic Liver Disease: A Systematic Review and Potential Clinical Applications - MDPI, accessed May 6, 2026, https://www.mdpi.com/2076-3921/12/7/1425
42. Rabdosia rubescens Inhibits CYP7A1 Expression and Induces ..., accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12512039/
43. Differential Effects of Resveratrol and Its Natural Analogs, Piceatannol and 3,5,4'-trans-trimethoxystilbene, on Anti-Inflammatory Heme oxigenase-1 Expression in RAW264.7 Macrophages - PubMed, accessed May 6, 2026, https://pubmed.ncbi.nlm.nih.gov/23861314/
44. Recent Advances in the Therapeutic Effects and Molecular Mechanisms of Baicalin - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12190052/
45. Differential Activities of the Two Closely Related Withanolides, Withaferin A and

Withanone: Bioinformatics and Experimental Evidences - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3433425/
46. Recent Advances in the Chemistry and Therapeutic Evaluation of Naturally Occurring and Synthetic Withanolides - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8840339/
47. Structure modification of luteolin and the influence of its derivatives on biological activities, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11936824/
48. Luteolin: a natural product with multiple mechanisms for atherosclerosis - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11983452/
49. Pueraria lobata-derived exosome-like nanovesicles alleviate osteoporosis by enhacning autophagy - PubMed, accessed May 6, 2026, https://pubmed.ncbi.nlm.nih.gov/37967723/
50. A combination of Pueraria lobata and Silybum marianum protects ..., accessed May 6, 2026, https://pubmed.ncbi.nlm.nih.gov/30836218/
51. A Decade of Molecular Understanding of Withanolide Biosynthesis and In vitro Studies in Withania somnifera (L.) Dunal: Prospects and Perspectives for Pathway Engineering - PMC, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC4661287/
52. Development of withaferin A analogs as probes of angiogenesis - PMC - NIH, accessed May 6, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3222585/